Apellis Pharmaceuticals, Inc. · NASDAQ:APLS
Apellis Pharmaceuticals — Q4 2024 Earnings Presentation
19 slides from Apellis Pharmaceuticals's earnings presentation, Feb 28, 2025
Slide 1: Fourth Quarter and Full Year 2024 Financial Results Conference Call
Fourth Quarter and Full Year 2024 Financial Results Conference Call February 28, 2025
Slide 2: Apellis Participants
Apellis Participants CEDRIC FRANCOIS, M.D., Ph.D. Co-Founder, President & Chief Executive Officer D AV I D A C H E S O N Executive Vice President of Commercial CAROLINE BAUMAL, M.D. Chief Medical Officer T I M O T H Y S U L L I VA N Chief Financial Officer 2
Slide 3: Forward-looking statements
Forward-looking statements Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act o
Slide 4: Our strategy is focused on three key pillars
Our strategy is focused on three key pillars Advance Transform the Maximize innovative treatment EMPAVELI’s pipeline, of GA with impact in rare leveraging our SYFOVRE diseases expertise in complement 4
Slide 5: Two commercial products with blockbuster potential
Two commercial products with blockbuster potential ✓ ~$612M in FY 2024 U.S. net product ✓ ~$98M in FY2024 U.S. net product revenue revenue ✓ Submitted sNDA in C3G and IC-MPGN; ✓ >510K SYFOVRE injections estimated U.S. launch expected in 2H25, if approved through December 2024 (including clinical tri
Slide 6: Advancing our pipeline, starting with first-ever gene editing approach to FcRn
Advancing our pipeline, starting with first-ever gene editing approach to FcRn Neonatal Fc receptor (FcRn) OPPORTUNITY FOR: First-ever, gene-edited FcRn One-time dosing Pre-clinical studies ongoing 6
Slide 7: SYFOVRE has a strong and differentiated profile
SYFOVRE has a strong and differentiated profile Consistently demonstrated robust and increasing effects over time Approved for as few as 6 doses per year In a preferred position with many payers 7
Slide 8: SYFOVRE remains the market leader in GA
SYFOVRE remains the market leader in GA • ~94K SYFOVRE doses delivered to ECP practices in 4Q 20241 • >60% total market share2 • >2,300 sites of care ordered SYFOVRE LTD1 1. ECP vial shipment data on file. 2. This is an estimate derived and extrapolated from available ECP injection demand data estim
Slide 9: Key initiatives to bring SYFOVRE to more GA patients
Key initiatives to bring SYFOVRE to more GA patients Broaden Amplify reach real-world data to eyecare with clinical analyses community & third-party evidence Educate payers Connect with patients on SYFOVRE’s differentiated value through new DTC proposition campaign 9
Slide 10: Preparing for potential EMPAVELI approval in C3G and IC-MPGN
Preparing for potential EMPAVELI approval in C3G and IC-MPGN • Submitted sNDA for approval • If approved, U.S. launch expected 2H 2025 • Pre-launch activities underway • Hiring field-based teams • Enhancing disease state awareness and market preparedness 10
Slide 11: Anticipate broad EMPAVELI adoption in C3G and IC-MPGN
Anticipate broad EMPAVELI adoption in C3G and IC-MPGN Post transplant ~5K C3G / IC-MPGN Severe patients estimated in U.S. 1 Moderate Mild 1. 2024 claims data analysis (patients with confirmed diagnosis). Servais et al. Kidney Int. 2012; 82(4): 454. Iatropoulos et al, Mol Immunol. 2016; 71: 131 11
Slide 12: EMPAVELI continues to elevate the standard of care in PNH
EMPAVELI continues to elevate the standard of care in PNH As of December 31, 2024: • ~$23 million in 4Q 2024 U.S. net product revenue • ~97% patient compliance rate • Continued strong safety profile with zero meningococcal infections due to encapsulated bacteria 12
Slide 13: Evidence supporting SYFOVRE use continues to grow
Evidence supporting SYFOVRE use continues to grow Pegcetacoplan: ~2 Foveal Areas Preserved Over 48 Months Nonsubfoveal (n=286) Results derived from a post hoc analysis. L. Singerman, “24-Month Results from the GALE Open-Label Extension Study: 48 Months of Continuous Pegcetacoplan,” presented at the
Slide 14: APL-3007 + SYFOVRE: next generation treatment blocking complement activity
APL-3007 + SYFOVRE: next generation treatment aimed at comprehensively blocking complement activity in the retina and choroid APL-3007 (siRNA) Phase 1 study in healthy volunteers Mean change from baseline in C3 Mean (±SE) % Change from Baseline in 0 • Strategic goal: evaluate potential for Complemen
Slide 15: Expanding EMPAVELI into new rare, kidney indications
Expanding EMPAVELI into new rare, kidney indications DELAYED GRAFT FUNCTION (DGF) PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) Approximately 13,000 patients in the DGF occurs in approximately 30-35% of US have primary FSGS1 deceased donor kidneys (~21,000 in the US in 2023)2 Plan to initiate tw
Slide 16: Consolidated fourth quarter and full year 2024 financial results
Consolidated fourth quarter and full year 2024 financial results (In USD Millions) Three Months Ended Dec 31, Twelve Months Ended Dec 31, 2024 2023 2024 2023 EMPAVELI U.S. Net Product Sales $23.4 $24.4 $98.1 $91.0 SYFOVRE U.S. Net Product Sales $167.8 $114.3 $611.8 $275.2 Licensing and Other Revenue
Slide 17: On track to deliver long-term profitable growth
On track to deliver long-term profitable growth 97% YoY Revenue Growth ~$806M ~$830M Cash and cash equivalents ~$781M of ~$411 million as of December 31, 2024 396.592 Expect existing cash and ~$397M projected revenues to fund operations to profitability Twelve months ending December 31, 2023 Twelve
Slide 18: Apellis is positioned for sustainable value creation
Apellis is positioned for sustainable value creation Maximizing two blockbuster opportunities with SYFOVRE and EMPAVELI Leveraging expertise in complement science to advance our pipeline and drive the next wave of therapeutic innovation On a path to profitability 18
Slide 19: Fourth Quarter and Full Year 2024 Financial Results Conference Call
Fourth Quarter and Full Year 2024 Financial Results Conference Call February 28, 2025
Apellis Pharmaceuticals — Q4 2024 Earnings Presentation on 6ix